Prostate Cancer Survival and Mortality according to a 13-year retrospective cohort study in Brazil: Competing-Risk Analysis.

Autor:	Braga SFM; Department of Preventive and Social Medicine, Faculty of Medicine, Graduate Program in Public Health, Universidade Federal de Minas Gerais - Belo Horizonte (MG), Brazil., Silva RPD; Department of Epidemiology and Biostatistics, Faculty of Medicine, Universidade Federal Fluminense - Niterói (RJ), Brazil.; Graduate Program in Statistics, Universidade Federal de Minas Gerais - Belo Horizonte (MG), Brazil., Guerra Junior AA; Department of Social Pharmacy, Faculty of Pharmacy, Graduate Program in Medicines and Pharmaceutical Assistance, Universidade Federal de Minas Gerais - Belo Horizonte (MG), Brazil., Cherchiglia ML; Department of Preventive and Social Medicine, Faculty of Medicine, Graduate Program in Public Health, Universidade Federal de Minas Gerais - Belo Horizonte (MG), Brazil.
Jazyk:	angličtina
Zdroj:	Revista brasileira de epidemiologia = Brazilian journal of epidemiology [Rev Bras Epidemiol] 2021 Jan 06; Vol. 24, pp. e210006. Date of Electronic Publication: 2021 Jan 06 (Print Publication: 2021).
DOI:	10.1590/1980-549720210006
Abstrakt:	Objective: To analyze cancer-specific mortality (CSM) and other-cause mortality (OCM) among patients with prostate cancer that initiated treatment in the Brazilian Unified Health System (SUS), between 2002 and 2010, in Brazil. Methods: Retrospective observational study that used the National Oncological Database, which was developed by record-linkage techniques used to integrate data from SUS Information Systems, namely: Outpatient (SIA-SUS), Hospital (SIH-SUS), and Mortality (SIM-SUS). Cancer-specific and other-cause survival probabilities were estimated by the time elapsed between the date of the first treatment until the patients' deaths or the end of the study, from 2002 until 2015. The Fine-Gray model for competing risk was used to estimate factors associated with patients' risk of death. Results: Of the 112,856 studied patients, the average age was 70.5 years, 21% died due to prostate cancer, and 25% due to other causes. Specific survival in 160 months was 75%, and other-cause survival was 67%. For CSM, the main factors associated with patients' risk of death were: stage IV (AHR = 2.91; 95%CI 2.73 - 3.11), systemic treatment (AHR = 2.10; 95%CI 2.00 - 2.22), and combined surgery (AHR = 2.30, 95%CI 2.18 - 2.42). As for OCM, the main factors associated with patients' risk of death were age and comorbidities. Conclusion: The analyzed patients with prostate cancer were older and died mainly from other causes, probably due to the presence of comorbidities associated with the tumor.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu